Is Remicade (Infliximab) an Immunosuppressant?
Yes, Remicade (infliximab) is definitively classified as an immunosuppressant that causes moderate-to-severe systemic immunosuppression.
Classification and Mechanism
Infliximab is categorized as an anti-TNF agent (tumor necrosis factor-alpha inhibitor), which falls under the umbrella of immunosuppressive medications used in inflammatory bowel disease and rheumatologic conditions. 1 The drug works by blocking TNF-alpha's interaction with its receptors, thereby inhibiting proinflammatory cytokines (IL-1, IL-6) and modulating immune effector cells including leukocytes, neutrophils, and eosinophils. 2
The 2021 ECCO guidelines explicitly list anti-TNF agents, including infliximab, among drugs causing moderate-severe immunosuppression. 1 This classification places infliximab in the same immunosuppression category as calcineurin inhibitors (ciclosporin, tacrolimus), tofacitinib, and high-dose methotrexate.
Clinical Implications of Immunosuppression
Infection Risk Profile
The immunosuppressive effects of infliximab create specific and clinically significant infection risks:
Mycobacterial and bacterial infections are particularly associated with anti-TNF agents, distinguishing them from other immunosuppressants (thiopurines carry higher viral infection risk, corticosteroids increase fungal/Candida risk). 1
Infliximab confers a particularly high infection risk compared to other IBD therapies including thiopurines, with retrospective studies and prospective registries demonstrating elevated risk for opportunistic infections. 1
Age amplifies risk dramatically: patients over 65 years treated with infliximab face up to a 20-fold increased risk of severe infections (11% vs 0.5% in younger patients). 1
Hepatitis B reactivation occurs in 39% of HBsAg-positive patients exposed to anti-TNF agents, significantly higher than other immunosuppressants. 3
Tuberculosis Considerations
The immunosuppressive nature of infliximab necessitates specific TB screening protocols:
All patients must undergo TB screening before starting infliximab, including clinical history, physical examination, chest radiograph, and tuberculin skin testing (if not already on immunosuppressive therapy). 4, 5
The majority of TB cases occur within three cycles of treatment (median 12 weeks), with extrapulmonary TB being common. 4, 5
Clinical TB awareness must continue throughout treatment and for 6 months after cessation of infliximab therapy. 4, 5
Vaccination Restrictions
Live vaccines are contraindicated in patients receiving infliximab due to its moderate-severe immunosuppression classification. 1 This is a direct clinical consequence of the drug's immunosuppressive properties and distinguishes it from medications causing no or selective immunosuppression (like vedolizumab or aminosalicylates).
FDA Labeling Confirmation
The FDA-approved labeling for infliximab products explicitly states: "RENFLEXIS may lower the ability of their immune system to fight infections." 6 The patient counseling section instructs physicians to inform patients about immunosuppression and the importance of reporting infection symptoms, including tuberculosis and hepatitis B reactivation. 6
Comparative Immunosuppression
While all anti-TNF agents cause immunosuppression, the degree of immunosuppression from anti-TNF agents is probably higher compared to ustekinumab and tofacitinib. 1 Combination therapy with infliximab plus other immunosuppressants (particularly thiopurines plus steroids plus infliximab) presents the greatest infection risk, with odds ratios increasing from 2.9 for one immunosuppressive drug to 14.5 for two or three. 1
Common Pitfalls to Avoid
Do not assume infliximab is "safer" because it's a biologic: The evidence clearly demonstrates it causes clinically significant immunosuppression with real infection consequences. 1
Do not skip TB screening: This is mandatory before initiation, as the immunosuppressive effects create substantial TB reactivation risk. 4, 5
Do not overlook age-related risk: Elderly patients (>65 years) require heightened vigilance due to dramatically increased severe infection rates. 1
Do not administer live vaccines: The moderate-severe immunosuppression classification makes this an absolute contraindication. 1